Clinical Trial, Phase 1/2 – Page 4

A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers

Post author:
Post published:May 9, 2025
Post category:

Cancer is a leading cause of death in California. Many cancers resist current therapies due to therapy-resistant cancer stem cells (CSCs). A team at UCSD is testing an antibody therapy…

Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes

Post author:
Post published:May 9, 2025
Post category:

ViaCyte is developing cell therapies to replace lost pancreatic beta cells for people with type 1 diabetes (T1D). The therapies are derived from human embryonic stem cells, which are partially…

Patient Support Program to Improve Accessibility to Eligible CIRM-Trial Patients

Post author:
Post published:May 9, 2025
Post category:

To help improve accessibility to eligible CIRM patients This project will allow patients in underserved communities in California equal access to clinical trials without bias due to financial circumstances.

A phase I/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19

Post author:
Post published:May 9, 2025
Post category:

Therapeutic Candidate or Device Human placental hematopoietic stem cell derived natural killer cells (CYNK-001) Indication SARS-CoV-2 positive patients requiring hospital admission and have any 2 out of 3 symptoms: fever,…

Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy

Post author:
Post published:May 9, 2025
Post category:

A phase 1/2 study to evaluate a bispecific CD19/CD20-directed CAR T cell, in refractory lupus nephritis and systemic lupus erythematosus

Post author:
Post published:May 9, 2025
Post category:

Therapeutic Candidate or Device IMPT-514 is an autologous T-cell product genetically modified to express a chimeric antigen receptor targeting CD19 and CD20 Indication Active, refractory lupus nephritis (LN) and systemic…

RPESC-RPE-4W Therapy for dry Age-related Macular Degeneration

Post author:
Post published:May 9, 2025
Post category:

Therapeutic Candidate or Device Retina pigment epithelial stem cell (RPESC)-derived RPE progeny at 4 weeks of differentiation (RPESC-RPE-4W) Indication Dry age-related macular degeneration (dry AMD). Therapeutic Mechanism Dry AMD involves…

Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A

Post author:
Post published:May 9, 2025
Post category:

Therapeutic Candidate or Device Investigational personalized antisense oligonucleotide drug (nL-SCN2A-002) Indication SCN2a-associated genetic disorder Therapeutic Mechanism The study participant has a pathogenic de novo p.R853Q gain-of-function amino acid substitution mutation…

The UCLA Delayed Immunological Tolerance after Kidney Transplantation Program

Post author:
Post published:May 9, 2025
Post category:

Therapeutic Candidate or Device CD34+ hematopoietic stem/progenitor cells (HSPC) and CD3+ cells Indication Phase I/II trial evaluating the safety/efficacy of infusion of donor CD34+ HSPCs and CD3+ T cells into…

Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

Post author:
Post published:May 9, 2025
Post category:

Therapeutic Candidate or Device ET140203 T cells: engineered T-cell therapy whereby autologous T cells are modified to specifically target and kill AFP+/ HLA-A2+ cancer cells. Indication Pediatric subjects aged ≥…

Subscribe to Receive CIRM News